At Serum Institute, His Royal Highness
Prince of Wales takes an update on MMR vaccines
On their maiden visit to the city, His
Royal Highness Prince of Wales and his wife Camilla Parker
Bowles on Sunday made a special stopover at the Serum Institute
of India. While the Prince of Wales interacted with scientists
and senior officials at the manufacturing facility, plants
globally, the Duchess of Cornwall paid a visit to the legendary
Poonawalla stud farm.
HRH attentively listened to the staff, asking questions about
pneumoccocal and MMR vaccines and was impressed with the
research and development laboratory.
HRH Prince of Wales
along with Dr. Cyrus Poonawalla & Mr. Adar Poonawalla at
the Serum Institute of India.
"It has taken a lot of effort and various
trips to the UK following which Prince Charles agreed to visit the
institute. Perhaps our work in saving children's lives was close to
his heart and he agreed to make this private visit to our facility,"
said Adar Poonawalla, Executive Director, Serum Institute of India.
"While there is no collaboration yet, we are already working with
several UK-based agencies (working in the field)," he added.
Adar Poonawalla and his father Dr. Cyrus Poonawalla, the chairman of
Poonawalla Group, introduced HRH to the representatives of key
agencies that Serum has been working with. More than 10-12 senior
scientists and directors, including S. R. Mundra, S. S. Jadhav, S.
Ravetkar, R. Dhere, M. Phadke and others, explained to HRH the work
done at the institute.
HRH
took special interest in the immunisation vaccine against
measles, mumps and rubella (MMR). In the UK, it had been a
subject of controversy after a paper was published on its
side-effects.
However, subsequent scientific studies showed the MMR vaccine
was safe. Charles wanted to know whether children were getting
vaccinated against MMR in India, scientists told Newsline.
HRH also met representatives of Rotary International Deepak
Shikarpur and MCCIA president S K Jain, enquiring about the
'zero polio' campaign.
Posters depicting the institute's work, such as the MenAfriVac
vaccine that has helped Unicef address the meningitis epidemic
in sub-Saharan Africa, were displayed at the hall. A major
project at the institute has been the rotavirus vaccine, the
phase III trials for which are currently on. A standalone
pneumococcal vaccine and a vero cell rabies vaccine are in the
late stages of development here.